AQR Capital Management
ZVRA icon

AQR Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

AQR Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.74M Buy
190,972
+111,057
+139% +$1.23M ﹤0.01% 2405
2026
Q1 		$745K Sell
79,915
-101,214
-56% -$912K ﹤0.01% 2920
2025
Q4 		$1.62M Buy
181,129
+28,818
+19% +$273K ﹤0.01% 2259
2025
Q3 		$1.45M Buy
+152,311
New +$1.53M ﹤0.01% 2199
2025
Q1 		– Sell
-11,728
Closed -$97.8K – 3208
2024
Q4 		$97.8K Buy
+11,728
New +$100K ﹤0.01% 2766
2022
Q3 		– Sell
-107,341
Closed -$479K – 2341
2022
Q2 		$479K Sell
107,341
-102,759
-49% -$468K ﹤0.01% 1702
2022
Q1 		$1.06M Buy
210,100
+149,668
+248% +$952K ﹤0.01% 1512
2021
Q4 		$526K Sell
60,432
-40,378
-40% -$360K ﹤0.01% 1808
2021
Q3 		$941K Buy
+100,810
New +$1.02M ﹤0.01% 1574

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AQR Capital Management's ZVRA Position: Q2 2026 in Review

AQR Capital Management increased its Zevra Therapeutics (ZVRA) stake by 139% in Q2 2026, buying an estimated $1.23M and bringing the position to 190,972 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2405.

AQR Capital Management first reported a position in ZVRA in Q3 2021 and has held it in 9 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • AQR Capital Management held 190,972 shares of Zevra Therapeutics worth $2.74M as of Q2 2026.
  • AQR Capital Management bought 111,057 Zevra Therapeutics shares in Q2 2026, an estimated $1.23M.
  • Zevra Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2405 holding.
  • AQR Capital Management first reported a position in Zevra Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.